#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3879182	F	Anti-thrombotic activity in Swiss albino mouse assessed as protection against collagen/epinephrine-induced pulmonary thromboembolism at 30 umol/kg, po administered 60 mins prior to thrombotic challenge relative to control	Mus musculus	26	ALA3877307	organism-based format	Scientific Literature
2.	ALA3879183	F	Anti-thrombotic activity in Swiss albino mouse assessed as protection against collagen/epinephrine-induced pulmonary thromboembolism administered orally 60 mins prior to thrombotic challenge relative to control	Mus musculus	11	ALA3877307	assay format	Scientific Literature
3.	ALA3879184	F	Anti-thrombotic activity in Swiss albino mouse assessed as protection against collagen/epinephrine-induced pulmonary thromboembolism at 30 umol/kg, po administered 60 mins prior to thrombotic challenge measured up to 24 hrs post dose relative to control	Mus musculus	1	ALA3877307	organism-based format	Scientific Literature
4.	ALA3879191	T	Toxicity in Swiss albino mouse assessed as bleeding time at 30 umol/kg, po	Mus musculus	1	ALA3877307	organism-based format	Scientific Literature
5.	ALA3879193	F	Anti-thrombotic activity in Swiss albino mouse model of FeCl3-induced arterial thrombosis assessed as prolongation of time to occlusion of carotid artery at 30 umol/kg, po	Mus musculus	1	ALA3877307	assay format	Scientific Literature
6.	ALA3879194	F	Anticoagulant activity in human plasma assessed as change in thrombin time at 10 to 100 uM	Homo sapiens	3	ALA3877307	cell-free format	Scientific Literature
7.	ALA3879195	F	Anticoagulant activity in human plasma assessed as change in prothrombin time at 10 to 100 uM	Homo sapiens	3	ALA3877307	cell-free format	Scientific Literature
8.	ALA3879196	F	Anticoagulant activity in human plasma assessed as change in activated partial thromboplastin time at 10 to 100 uM	Homo sapiens	3	ALA3877307	cell-free format	Scientific Literature
9.	ALA3879197	F	Antiplatelet activity in human platelet rich plasma assessed as inhibition of TRAP-induced platelet aggregation at 100 uM preincubated for 5 mins followed by TRAP addition measured after 5 mins by turbidimetric method	Homo sapiens	3	ALA3877307	cell-free format	Scientific Literature
10.	ALA3879198	F	Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 100 uM preincubated for 5 mins followed by ADP addition measured after 5 mins by turbidimetric method	Homo sapiens	3	ALA3877307	cell-free format	Scientific Literature
11.	ALA3879199	F	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 100 uM preincubated for 5 mins followed by arachidonic acid addition measured after 5 mins by turbidimetric method	Homo sapiens	3	ALA3877307	cell-free format	Scientific Literature
12.	ALA3879200	B	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 5 mins followed by collagen addition measured after 5 mins by turbidimetric method	Homo sapiens	5	ALA3877307	cell-free format	Scientific Literature
13.	ALA3879203	B	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of platelet adhesion to fibrillar collagen at 10 to 300 uM preincubated with platelets for 30 mins followed by platelet adhesion to collagen measured after 1 hr in absence of Mg2+ by colorimetric method	Homo sapiens	1	ALA3877307	cell-free format	Scientific Literature
14.	ALA3879204	B	Antagonist activity at GP1a/GP2a receptor in human platelet rich plasma assessed as inhibition of platelet adhesion to fibrillar collagen at 10 to 100 uM preincubated with platelets for 30 mins followed by platelet adhesion to collagen measured after 1 hr in presence of Mg2+ by colorimetric method	Homo sapiens	1	ALA3877307	cell-free format	Scientific Literature
15.	ALA3879205	B	Antagonist activity at GP1b/GP9/GP5 receptor in human platelet rich plasma assessed as inhibition of ristocetin-induced platelet aggregation at 100 uM preincubated for 5 mins followed by ristocetin addition measured after 5 mins by turbidimetric method	Homo sapiens	1	ALA3877307	cell-free format	Scientific Literature
16.	ALA3879206	B	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of CRP-XL-induced platelet aggregation preincubated for 5 mins followed by CRP-XL addition measured after 5 mins by turbidimetric method	Homo sapiens	5	ALA3877307	cell-free format	Scientific Literature
17.	ALA3879207	B	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of CVX-induced platelet aggregation preincubated for 5 mins followed by CVX addition measured after 5 mins by turbidimetric method	Homo sapiens	5	ALA3877307	cell-free format	Scientific Literature
18.	ALA3879208	B	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of collagen-induced P-selectin expression preincubated for 10 mins followed by collagen addition measured after 10 mins by flow cytometry	Homo sapiens	1	ALA3877307	cell-free format	Scientific Literature
19.	ALA3879209	A	Effect on basal P-selectin expression in human platelet rich plasma at 30 to 300 uM by flow cytometry	Homo sapiens	1	ALA3877307	cell-free format	Scientific Literature
20.	ALA3879210	B	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of collagen-induced ATP release preincubated for 10 mins followed by collagen addition measured after 10 mins by luciferase reporter gene assay	Homo sapiens	1	ALA3877307	cell-free format	Scientific Literature